Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Live webcast to be held on September 24th at 12:00 p.m. EDT Live webcast to be held on September 24th at 12:00 p.m. EDT

Zentalis Pharmaceuticals to Host a Key Opinion Leader Virtual Meeting to Discuss its Investigational WEE1 Inhibitor ZN-c3 and its Potential as a Best-in-Class Treatment for Advanced Solid Tumors

NEW YORK and SAN DIEGO, Sept.  01, 2020  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Alexis Pinto as Chief Legal Officer. Ms. Pinto joins Zentalis with over 20 years of legal and strategic business development experience in the healthcare industry, most recently at Celgene Corporation.

Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer

Closed initial public offering (IPO) of common stock, raising gross proceeds of ~$190.0 million   Raised an additional ~$144.4 million in gross proceeds from recent follow-on offering   Completed a $20.0 million Series A financing to establish Zentera Therapeutics, a majority-owned Chinese joint venture   Entered into strategic collaborations with Eli Lilly and Tavros Therapeutics to further advance oncology pipeline

Zentalis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Update

NEW YORK and SAN DIEGO, July  29, 2020  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten public offering of 4,125,000 shares of its common stock at a public offering price of $35.00 per share, for total gross proceeds of approximately $144.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. The offering is expected to close on August 3, 2020, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 618,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Zentalis Pharmaceuticals Announces Pricing of Upsized Offering of Common Stock

NEW YORK & SAN DIEGO, July  27, 2020  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a clinical collaboration agreement with Eli Lilly and Company (NYSE: LLY, “Lilly”) in which Zentalis will evaluate the combination of ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, and Verzenio® (abemaciclib), Lilly’s CDK4 and 6 inhibitor, in patients with ER+/HER2- advanced breast cancer.

Zentalis Pharmaceuticals Enters into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib, a CDK4 and 6 Inhibitor

NEW YORK and SAN DIEGO, July  01, 2020  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Blackwell, M.D. to its Board of Directors. Dr. Blackwell is a renowned breast cancer researcher who has made significant contributions to the biopharmaceutical industry for more than two decades. 

Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors

Bio-Rad Laboratories

Forma Therapeutics Holdings

IMARA

Keros Therapeutics

Vaxcyte

Avidity Biosciences

Repare Therapeutics

SPDR S&P Biotech ETF

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Biotech IPOs are booming -- but it's not all about Covid-19

NEW YORK and SAN DIEGO, June  15, 2020  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

Zentalis Pharmaceuticals to Present Preclinical Data on ZN-c5 at the Upcoming AACR Virtual Annual Meeting II

The company's share price has nearly tripled since its IPO less than two months ago. Is it too late to get in on the fun?

Is It Too Late to Jump In on Zentalis?

NEW YORK, SAN DIEGO and DURHAM, N.C., May  28, 2020  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply Tavros’ functional genomic discovery platform to develop next generation targeted small molecule drug candidates, initially to expand Zentalis’ oncology pipeline.

Zentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule Therapies

Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China

Zentalis Pharmaceuticals (ZNTL) Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics

Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics

Completed initial public offering of common stock, raising approximately $190.0 million in gross proceeds

Zentalis Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Update

ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years

Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies

These companies just raised significant cash to advance promising drug pipelines.

These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?

Biotech pharmaceutical company Zentalis Pharmaceuticals has launched a successful IPO that values the company at over $730 million.

Zentalis IPO: A Strong Biotech IPO In The Current Market

News for Zentalis Pharmaceuticals Stock (ZNTL)